{{ $ActivityName }}
A. Clinical examination
B. IgE levels
C. Blood tests
D. Serum skin tests
A. < 15 years
B. 15-30 years
C. 30-50 years
D. 50 years and above
A. Upto 10%
B. 10-30%
C. 30-50%
D. >50%
A. Male
B. Female
A. Anti-TPO antibodies
B. CRP
C. ASST
D. IgE
E. CBC
F. Any other
A. Upto 2 weeks
B. 2-4 weeks
C. 4-6 weeks
D. >6 weeks
A. Upto 50%
B. 50-60%
C. 60-70%
D. 70-80%
E. >80%
A. Double dose of anti-histamines
B. Add one more second generation non-sedative antihistamine
C. Anti-histamines plus cyclosporine
D. Anti-histamines plus omalizumab
E. Omalizumab plus cyclosporine
A. upto 20%
B. 20-30%
1
2
3
4
A. UAS
B. UAS7
C. UCT
D. Any other
A. Montelukast
B. Ranitidine
C. Dapsone
D. Methotrexate
E. Any other
A. Yes
B. No
A. More Effective than other second-generation antihistamines
B. Faster results than other second-generation antihistamines
C. Tolerability/safety
D. All of the above
A. Very much improved
B. Improved
C. Unchanged
D. Minimally Worse
E. Worse
A. Very well tolerated
B. Well tolerated
C. Not well tolerated
D. Serious side effects are reported frequently